Studying Different Doses and Frequencies of ADVATE FVIII Treatment for Boys with Hemophilia A and Inhibitors in a Multicenter Phase 4 Clinical Trial

What this Trial Is About

This research focuses on boys with Hemophilia A who have developed inhibitors against factor VIII FVIII treatment. Hemophilia A is a genetic bleeding disorder caused by deficient FVIII, leading to frequent bleeding episodes that can cause joint damage and long-term health problems. Inhibitors are antibodies that neutralize FVIII and make standard replacement therapy ineffective, representing a major treatment challenge. The study aims to evaluate the safety and effectiveness of various dosing regimens of immune tolerance induction ITI therapy using FVIII to eradicate these inhibitors and improve patient outcomes. Participants receive different doses and frequencies of ADVATE4, a recombinant FVIII product, to induce immune tolerance. The study includes multiple groups based on inhibitor levels and treatment history low inhibitor titer groups receive either non-daily or daily doses of 50 or 100 IUkg high inhibitor titer groups receive low, medium, or high doses of ADVATE, some combined with immunosuppressive agents for those with poor prognosis. This multicenter, open-label trial is designed to explore the impact of dose and frequency on ITI success and to examine related biomarkers. During the study, boys up to 18 years old with severe Hemophilia A and inhibitors will be closely monitored over 24 months to assess treatment success. Researchers will track inhibitor levels, immune markers, bleeding episodes, and safety outcomes. Patients undergo regular infusions of ADVATE according to assigned dosing schedules, with clinical assessments and laboratory tests to evaluate immune tolerance induction. The study also aims to identify predictors of ITI outcomes and relapse risks to improve personalized treatment strategies for children with Hemophilia A and inhibitors.

Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)